Objective:

To synthesize current knowledge on the pathophysiology, diagnosis, and management of autoimmune gastritis (AIG), focusing on familial aggregation, polyglandular autoimmunity, diagnostic challenges, and emerging therapeutic strategies.

Approach:

Key Findings:

• AIG is characterized by the immune-mediated destruction of gastric parietal cells, leading to vitamin B12 deficiency and increased gastric malignancy risk, with systemic manifestations.
• The global prevalence of AIG is approximately 3.85%, with higher incidence in women and associations with other autoimmune conditions.
• Endoscopic surveillance and individualized risk stratification are essential due to the increased risk of gastric neuroendocrine tumors and gastric adenocarcinoma, highlighting the need for proactive screening.

Interpretation:

The review emphasizes the need for improved awareness and diagnostic strategies for AIG, particularly in asymptomatic early stages, and the importance of proactive screening in high-risk populations.

Limitations:

• The article does not provide specific data on the effectiveness of emerging therapeutic options.
• The clinical examples presented are original and unpublished, limiting generalizability, and the underdiagnosis due to asymptomatic early stages is a significant concern.

Conclusion:

The review provides a comprehensive framework for clinicians to navigate the complexities of AIG, aiming to improve patient outcomes and mitigate malignancy risks.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.